JNJ vs MCK
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
Side-by-side fundamentals
| Metric | JNJ | MCK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $256.48 | $930.25 | |
| Market cap | $618.1B | $108.5B | |
| P/E as of 2026-10-08 | 29.74 | 24.91 | MCK lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 1.63 | |
| Net margin | +28.5% | +1.2% | JNJ higher |
| Gross margin | +67.9% | +3.6% | JNJ higher |
| Operating margin FY2026, SEC XBRL | n/a | +1.5% | |
| ROE FY2025, SEC XBRL | +32.9% | n/a | |
| ROA | +13.5% | +5.8% | JNJ higher |
| Debt / equity as of 2026-09-02 | 0.58 | 1.29 | JNJ lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.1% | +8.8% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +13.4% | MCK higher |
| Dividend yield as of 2026-09-02 | +2.0% | +0.4% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 19 | MCK higher |
| Beta as of 2026-09-02 | -0.02 | 0.06 | |
| 1-year return as of 2026-10-08 close | +35.2% | +23.1% | JNJ higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.